Category: piperazines

Palbociclib regulates intracellular lipids in mammary tumor cells by secreting lipoprotein lipase was written by Fujii, Tomoyasu;Kamishikiryo, Jun;Morita, Tetsuo. And the article was included in Pharmacological Reports in 2022.SDS of cas: 571190-30-2 This article mentions the following:

Lipoprotein metabolism is essential for the growth and proliferation of cancer cells, and is involved in the supply of energy and cellular components. Lipoprotein lipase (LPL) is a very important enzyme in lipoprotein metabolism; however, the details underlying the mechanism of LPL secretion are unclear. Palbociclib is an antitumor drug that inhibits cell cycle progression and suppresses the growth of cancer cells. The effects of palbociclib on energy metabolism, particularly on lipid metabolism, have not been fully elucidated. We examined the regulation of LPL secretion, which is primarily involved in lipoprotein metabolism FM3A mouse mammary tumor cells, which are hormone receptor-pos. breast cancer cells, were treated with palbociclib, and the activity and protein levels of secreted LPL were measured. Moreover, the changes in intracellular lipid content were measured by fluorescence staining using Nile Red. FM3A cells were treated with palbociclib, the activity and protein content of secreted LPL were increased. The stimulatory secretion of LPL by palbociclib was suppressed by an intracellular Ca²⁺ chelator (BAPTA-AM) and a Ca²⁺/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (STO-609). Furthermore, the palbociclib-stimulated secretion of LPL was not observed in AMP-activated protein kinase (AMPK)-knockdown cells. An increase in the fluorescence intensity of Nile Red was observed in palbociclib-treated cells; however, no increase was observed in LPL-knockdown cells. Our data suggest that palbociclib causes intracellular lipid accumulation in breast cancer cells by stimulating Ca²⁺/CaMKK/AMPK-mediated LPL secretion. In the experiment, the researchers used many compounds, for example, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2SDS of cas: 571190-30-2).

6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2) belongs to piperazine derivatives. The piperazine scaffold is often found in biologically active compounds in different therapeutic areas. These therapeutic areas include antifungals, antidepressants, antivirals, and serotonin receptor (5-HT) antagonists/agonists. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).SDS of cas: 571190-30-2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Health effects and risks associated with the occurrence of pharmaceuticals and their metabolites in marine organisms and seafood was written by Madikizela, Lawrence Mzukisi;Ncube, Somandla. And the article was included in Science of the Total Environment in 2022.SDS of cas: 98105-99-8 This article mentions the following:

Pharmaceuticals and their metabolites are continuously invading the marine environment due to their input from the land such as their disposal into the drains and sewers which is mostly followed by their transfer into wastewater treatment plants (WWTPs). Their incomplete removal in WWTPs introduces pharmaceuticals into oceans and surface water. To date, various pharmaceuticals and their metabolites have been detected in marine environment. Their occurrence in marine organisms raises concerns regarding toxic effects and development of drug resistant genes. Therefore, it is crucial to review the health effects and risks associated with the presence of pharmaceuticals and their metabolites in marine organisms and seafood. This is an important study area which is related to the availability of seafood and its quality. Hence, this study provides a critical review of the information available in literature which relates to the occurrence and toxic effects of pharmaceuticals in marine organisms and seafood. This was initiated through conducting a literature search focussing on articles investigating the occurrence and effects of pharmaceuticals and their metabolites in marine organisms and seafood. In general, most studies on the monitoring of pharmaceuticals and their metabolites in marine environment are conducted in well developed countries such as Europe while research in developing countries is still limited. Pharmaceuticals present in freshwater are mostly found in seawater and marine organisms. Furthermore, the toxicity caused by different pharmaceutical mixtures was observed to be more severe than that of individual compounds In the experiment, the researchers used many compounds, for example, 6-Fluoro-1-(4-fluorophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (cas: 98105-99-8SDS of cas: 98105-99-8).

6-Fluoro-1-(4-fluorophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (cas: 98105-99-8) belongs to piperazine derivatives. Piperazine belongs to the family of medicines called anthelmintics. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).SDS of cas: 98105-99-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Effects of 1-[bis(4-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (KB-2796) on cerebral circulation in dogs was written by Morita, Tominori;Iwamoto, Takahiro;Harada, Kengo;Hara, Hideaki;Sukamoto, Takayuki;Ito, Keizo;Nurimoto, Seiichi. And the article was included in Oyo Yakuri in 1993.Application of 101477-54-7 This article mentions the following:

The effects of 1-[bis(4-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (KB-2796, I), a new calcium antagonist, on cerebral circulation were studied in anesthetized dogs. KB-2796 increased the vertebral blood flow when injected into the vertebral artery (3-300 渭g/kg) or into the vein (30-1,000 渭g/kg) or introduced into the duodenum (3 or 10 mg/kg) in anesthetized dogs. KB-2796 was more potent than flunarizine and papaverine in increasing the flow rate. The duration of action of KB-2796 was longer than that of papaverine and compatible to that of flunarizine. The effect of KB-2796 injected into the vertebral artery in increasing the vertebral blood flow was not affected by pretreatment with propranolol, atropine, chlorpheniramine or aminophylline in anesthetized dogs. Furthermore, KB-2796 (i.v.) did not potentiate the effect of adenosine. KB-2796 (0.1 and 0.3 mg/kg, i.v.) and flunarizine (1 mg/kg, i.v.) increased the cerebral blood flow without modifying cerebral oxygen consumption in pancronium-immobilized anesthetized dogs. The results suggest that KB-2796 increases the cerebral blood flow presumably through vasodilation of the cerebral vessels by blocking calcium channels. In the experiment, the researchers used many compounds, for example, 1-(Bis(4-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (cas: 101477-54-7Application of 101477-54-7).

1-(Bis(4-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (cas: 101477-54-7) belongs to piperazine derivatives. A form in which piperazine is commonly available industrially is as the hexahydrate, C4H10N2. 6H2O, which melts at 44 掳C and boils at 125鈥?30 掳C. Intermediate for a wide range of pharmaceuticals, polymers, dyes, corrosion inhibitors, rubber accelerators and surfactants.Application of 101477-54-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Overall Shape Constraint of Alternating 伪/尾-Hybrid Peptides Containing Bicyclic 尾-Proline was written by Wang, Siyuan;Otani, Yuko;Zhai, Luhan;Su, Aoze;Nara, Masayuki;Kawahata, Masatoshi;Yamaguchi, Kentaro;Sada, Akane;Ohki, Rieko;Ohwada, Tomohiko. And the article was included in Organic Letters in 2019.Formula: C30H30Cl2N4O4 This article mentions the following:

Our NMR, IR/Raman, CD spectroscopic, and X-ray crystallog. studies, as well as accelerated mol. dynamics simulations, showed that alternating hybrid 伪/尾-peptides containing a bicyclic 尾-proline surrogate form unique extended curved folds, regardless of the peptide length and solvent environment. It is suggested that extended 尾/PPII structures are preferred in the insulating 伪-alanine moieties between the rigid bicyclic 尾-proline structures. These hybrid peptides inhibit p53-MDM2 and p53-MDMX protein-protein interactions. In the experiment, the researchers used many compounds, for example, 4-(cis-4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one (cas: 548472-68-0Formula: C30H30Cl2N4O4).

4-(cis-4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one (cas: 548472-68-0) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).Formula: C30H30Cl2N4O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. was written by Gharib, Khalil El;Macaron, Walid;Kattan, Joseph;Salloum, Mohamad Ali;Farhat, Fadi;Smith, Marianne;Karak, Fadi El. And the article was included in Current problems in cancer in 2022.Computed Properties of C24H29N7O2 This article mentions the following:

CDK 4/6 inhibitors have been yielding propitious results when with hormone therapy in the management of Her2-negative and hormone-receptor (HR)-positive metastatic breast cancer, palbociclib being one of the first molecules investigated in this setting. However, the response to CDK4/6 inhibitors is variable. To identify predictive and prognostic factors of response to this therapeutic regimen. Eligible patients were females with HR+ and Her2- advanced breast cancer, receiving Palbociclib in combination with Letrozole. PFS was the primary endpoint in the evaluation of response to treatment. This survival was then further segregated according to various characteristics: histological (type, grade, hormone receptors), metastatic site, line of treatment, response type at initial assessment, and best response achieved. The data was then processed by two statistical analysis models: Kaplan-Meier and univariate preceding multivariate Cox proportional risks. Sixty patients were included and followed for a median follow-up duration of 15.98 months. PFS recorded a median of 19.07 months (95% CI=15.43-22.71). PFS had a median of 12.99 months in the absence of progesterone receptors (vs 20.05 months in the case of positive estrogen and progesterone receptors; P聽=聽0.046), a median of 13.02 months in the presence of liver metastases (vs 22.98 months in the absence of liver metastases; P聽=聽0.007), and 15.94 months in the case of second-line and beyond (vs 22.98 months in the case of first-line; P聽=聽0.033). Regarding the Hazard Ratio of progression, we note age (HR 0.941; P聽=聽0.019), liver metastases (HR 2.751; P聽=聽0.051), response at initial evaluation (HR<1; P < 0.001) and best response (HR<1; P聽=聽0.003). PFS reached similar figures to those of international studies. The absence of progesterone receptors, presence of liver metastases, and use as second-line or beyond are associated with a reduced median PFS. One year age increase (protective factor), liver metastases (risk factor), response at initial evaluation, and best response achieved are identified as the most predictive factors of the response to this treatment regimen and of the progression risk. In the experiment, the researchers used many compounds, for example, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2Computed Properties of C24H29N7O2).

6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2) belongs to piperazine derivatives. The piperazine scaffold is often found in biologically active compounds in different therapeutic areas. These therapeutic areas include antifungals, antidepressants, antivirals, and serotonin receptor (5-HT) antagonists/agonists. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Computed Properties of C24H29N7O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. was written by Earley, Willie;Guo, Hua;Daniel, David;Nasrallah, Henry;Durgam, Suresh;Zhong, Yan;Patel, Mehul;Barab谩ssy, 脕gota;Szatm谩ri, Bal谩zs;N茅meth, Gy枚rgy. And the article was included in Schizophrenia research in 2019.Safety of 3-(trans-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea This article mentions the following:

Although currently approved antipsychotics exert efficacy on positive symptoms of schizophrenia, treatments for negative symptoms remain a major unmet need. Post hoc analyses were used to investigate the possible efficacy of cariprazine in patients with moderate/severe negative symptoms of schizophrenia and no predominance of positive symptoms. Data were pooled from 2 randomized, double-blind, placebo- and active-controlled cariprazine studies in patients with acute schizophrenia (NCT00694707, NCT01104766). Analyses included data from a subset of patients with a Positive and Negative Syndrome Scale factor score for negative symptoms (PANSS-FSNS) 鈮?4, PANSS factor score for positive symptoms (PANSS-FSPS) 鈮?9, and scores of 鈮? on 鈮? of 3 PANSS items (blunted affect [N1], passive/apathetic social withdrawal [N4], lack of spontaneity/flow of conversation [N6]). Changes from baseline to week 6 in PANSS-FSNS were evaluated in the following treatment groups: placebo (n鈥?鈥?9), cariprazine 1.5-3 (n鈥?鈥?4) and 4.5-6鈥痬g/d (n鈥?鈥?6), risperidone 4鈥痬g/d (n鈥?鈥?4), or aripiprazole 10鈥痬g/d (n鈥?鈥?4). Significant differences were observed versus placebo for cariprazine (1.5-3鈥痬g/d, P鈥?鈥?0179; 4.5-6鈥痬g/d, P鈥?鈥?0002) and risperidone (P鈥?鈥?0149), but not aripiprazole (P鈥?鈥?3265), and versus aripiprazole for cariprazine 4.5-6鈥痬g/d (P鈥?鈥?0197). After adjusting for positive symptom changes, differences versus placebo remained statistically significant for cariprazine (1.5-3鈥痬g/d, P鈥?鈥?0322; 4.5-6鈥痬g/d, P鈥?鈥?0038) but not for risperidone (P鈥?鈥?2204). PANSS-FSNS response (鈮?0% reduction from baseline) rates were significantly higher with cariprazine (1.5-3鈥痬g/d鈥?鈥?4.3%, P鈥?鈥?0194; 4.5-6鈥痬g/d鈥?鈥?9.7%, P鈥?鈥?0001) than placebo (35.4%). In patients with acute schizophrenia and moderate/severe negative symptoms, cariprazine was associated with significantly greater improvement in negative symptoms compared with placebo and aripiprazole, warranting further exploration of the efficacy of cariprazine on negative symptoms. In the experiment, the researchers used many compounds, for example, 3-(trans-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea (cas: 839712-12-8Safety of 3-(trans-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea).

3-(trans-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea (cas: 839712-12-8) belongs to piperazine derivatives. A form in which piperazine is commonly available industrially is as the hexahydrate, C4H10N2. 6H2O, which melts at 44 掳C and boils at 125鈥?30 掳C. Piperazine and its salts did not induce point mutations in a bacterial test. A series of mutagenicity studies in cells, both in vitro and in vivo, has been completed and showed no evidence of mutagenic effect.Safety of 3-(trans-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Identification of Binding Specificity-Determining Features in Protein Families was written by Anderson, Peter C.;De Sapio, Vincent;Turner, Kevin B.;Elmer, Sidney P.;Roe, Diana C.;Schoeniger, Joseph S.. And the article was included in Journal of Medicinal Chemistry in 2012.Formula: C24H27FN6O4 This article mentions the following:

The authors present a new approach for identifying features of ligand-protein binding interfaces that predict binding selectivity and demonstrate its effectiveness for predicting kinase inhibitor specificity. The authors analyzed a large set of human kinases and kinase inhibitors using clustering of exptl. determined inhibition constants (to define specificity classes of kinases and inhibitors) and virtual ligand docking (to extract structural and chem. features of the ligand-protein binding interfaces). The authors then used statistical methods to identify features characteristic of each class. Machine learning was employed to determine which combinations of characteristic features were predictive of class membership and to predict binding specificities and affinities of new compounds Experiments showed predictions were 70% accurate. The authors’ method can automatically pinpoint on the three-dimensional binding interfaces pharmacophore-like features that act as selectivity filters. The method is not restricted to kinases, requires no prior hypotheses about specific interactions, and can be applied to any protein families for which sets of structures and ligand binding data are available. In the experiment, the researchers used many compounds, for example, 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate (cas: 692737-80-7Formula: C24H27FN6O4).

4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate (cas: 692737-80-7) belongs to piperazine derivatives. Piperazine was first introduced as an anthelmintic in 1953. Piperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Formula: C24H27FN6O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Copper iodide nanoparticles supported on magnetic aminomethylpyridine functionalized cellulose: a new heterogeneous and recyclable nanomagnetic catalyst for facile access to N-sulfonylamidines under solvent free conditions was written by Ghasemi, Zarrin;Shojaei, Salman;Shahrisa, Aziz. And the article was included in RSC Advances in 2016.Application of 14172-55-5 This article mentions the following:

In this study, a highly active catalyst based on copper iodide nanoparticles supported on magnetic aminomethylpyridine functionalized cellulose has been synthesized and characterized. Its catalytic activity was investigated in the multicomponent synthesis of N-sulfonylamidines via an in situ generated sulfonyl ketenimine intermediate under solvent free conditions at room temperature The desired products were obtained in good to excellent yields at short reaction times. Based on observed results, the synthesized catalyst was an efficient, magnetically separable, recyclable and green catalyst from a natural source. In the experiment, the researchers used many compounds, for example, 1-(Phenylsulfonyl)piperazine (cas: 14172-55-5Application of 14172-55-5).

1-(Phenylsulfonyl)piperazine (cas: 14172-55-5) belongs to piperazine derivatives. Simple N-substituted piperazines have been found in many drug molecules. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).Application of 14172-55-5

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Optimization for QuEChERS extraction of mycotoxins and veterinary drugs by response surface methodology for application to egg and milk was written by Zhou, Jian;Xu, Jiao-Jiao;Cong, Jin-Mi;Cai, Zeng-Xuan;Zhang, Jing-Shun;Wang, Jun-Lin;Ren, Yi-Ping. And the article was included in Journal of Chromatography A in 2018.Formula: C19H20F3N3O3 This article mentions the following:

A multiclass method was proposed for the simultaneous determination of various classes of veterinary drugs (n = 65), mycotoxins and metabolites (n = 39) in egg and milk by ultra-high performance liquid chromatog.-tandem mass spectrometry. The contaminants were extracted by QuEChERS-based strategy including salt-out partitioning and dispersive solid-phase extraction for cleanup further. With the aim of maximizing throughput and extraction efficiency, Plackett-Burman design was employed initially for screening significant variables. And response surface methodol. based on central composite design was conducted to achieve optimal conditions in details: 3.35% (volume/volume) of formic acid in acetonitrile, 1.2 g of NaCl, 0.5 g of anhydrous NaAc, 300 mg of C18 and 140 mg of primary secondary amine. Satisfactory anal. characteristics in validation, in aspects of accuracy (70%-105% for mycotoxins and quinolones, 55%-80% for sulfonamides and 40%-105% for other veterinary drugs), precision (inter-day RSDs < 14%) and sensitivity (LOQs ranged from 0.01 渭g/kg to 31 渭g/kg), were achieved under the optimized conditions. The matrix effects were evaluated and compensated by the use of matrix-matched calibration curves (R² > 0.987). In practice, 45 eggs and 30 milk samples were investigated by the established method, of which pos. finding aflatoxin in milk and sterigmatocystin in eggs. In the experiment, the researchers used many compounds, for example, 1-Cyclopropyl-7-(cis-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (cas: 113617-63-3Formula: C19H20F3N3O3).

1-Cyclopropyl-7-(cis-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (cas: 113617-63-3) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Piperazine is an anthelminthic especially useful in the treatment of partial intestinal obstruction caused by Ascaris worms, which is a condition primarily seen in children. Piperazine hydrate and piperazine citrate are the main anthelminthic piperazines.Formula: C19H20F3N3O3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Synthesis of lomerizine dihydrochloride was written by Xu, Changsheng;Chen, Guohua;Luo, Xiaochuan. And the article was included in Zhongguo Yaoke Daxue Xuebao in 2002.Formula: C27H32Cl2F2N2O3 This article mentions the following:

Lomerizine dihydrochloride, a calcium antagonist used as antimigraine drug, was synthesized by methylating pyrogallic acid with di-Me sulfate to afford 1,2,3-trimethoxybenzene, chloromethylating with paraformaldehyde to afford 2,3,4-trimethoxybenzyl chloride, substituting with bis(4-fluorobenzyl)methylpiperazine in presence of triethylamine. Lomerizine dihydrochloride was obtained with 43% overall yield from pyrogallic acid. The structure of the compound was confirmed by IR, ¹H-NMR, MS, and elemental anal. In the experiment, the researchers used many compounds, for example, 1-(Bis(4-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (cas: 101477-54-7Formula: C27H32Cl2F2N2O3).

1-(Bis(4-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (cas: 101477-54-7) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).Formula: C27H32Cl2F2N2O3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics